12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Thu, 09 Oct 2025 10:09:37 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Cache-Control: no-cache, private [5] => Cache-Control: no-cache, no-store, must-revalidate [6] => Nel: {"report_to":"cf-nel","success_fraction":0.0,"max_age":604800} [7] => x-frame-options: SAMEORIGIN [8] => x-content-type-options: nosniff [9] => x-xss-protection: 1; mode=block [10] => referrer-policy: strict-origin-when-cross-origin [11] => permissions-policy: geolocation=(), microphone=(), camera=() [12] => content-security-policy: default-src * 'unsafe-inline' 'unsafe-eval' data: blob:; script-src * 'unsafe-inline' 'unsafe-eval' data: blob:; style-src * 'unsafe-inline' data:; img-src * data: blob:; font-src * data:; connect-src *; frame-src *; object-src *; media-src *; child-src *; [13] => Server: cloudflare [14] => x-robots-tag: noindex, nofollow, nosnippet, noarchive [15] => strict-transport-security: max-age=31536000; includeSubDomains; preload [16] => expires: Fri, 10 Oct 2025 10:09:36 GMT [17] => vary: Accept-Encoding [18] => Report-To: {"group":"cf-nel","max_age":604800,"endpoints":[{"url":"https://a.nel.cloudflare.com/report/v4?s=3ZFFsEQS1RS6%2FUmU7sHvP7zUbIdtrCLdCZNZ4LSSzMAVW98u0Vwk4sTaWMj0m%2BnCEsBqxyOdG%2B5SKqyhPvdJvXR8ZB2ojH8hGumqlGY%3D"}]} [19] => cf-cache-status: DYNAMIC [20] => Speculation-Rules: "/cdn-cgi/speculation" [21] => Server-Timing: cfCacheStatus;desc="DYNAMIC" [22] => Server-Timing: cfEdge;dur=2,cfOrigin;dur=89 [23] => Set-Cookie: UpalLiveSession=eyJpdiI6Im8zYkJJNW5qd3MzdEUrS1NcL21Reit3PT0iLCJ2YWx1ZSI6InlVQVpaeitacElFRlNORGtSNlQ3WnU5NGpRNUthS2d6YnVcLzhrVVwvN2czRWlCTVFVY2pacXlqaXpGRWtUY0U2SVN1YnptREt6XC9WdWNjM2pmZU5rdzZRPT0iLCJtYWMiOiJhNjcxNGUxOTAxYzVmYWZjMmVkM2Y3MTcxYTZlYTY3NzgwY2U3MmZmMzQxNTE5ZDM0MGE0YjA1NDUxN2MyYjFiIn0%3D; HttpOnly; Path=/; Max-Age=94608000; Expires=Sun, 08 Oct 2028 10:09:37 GMT [24] => CF-RAY: 98bd155ddb91cf0c-KUL [25] => alt-svc: h3=":443"; ma=86400 ) 789

中国国家中医药管理局周日指出，首批国家援鄂抗疫中医医疗队所研制的化湿败毒颗粒，在周三获得临床试验批件，为首个治疗新冠肺炎的中药临床批件。

化湿败毒方是中国国家首批中医医疗队在金银潭医院以及东西湖方舱医院的实际救治过程中，医疗队“边救治，边总结”过程中逐步形成的。

化湿败毒方有2个特点，第一是消灭病毒，第二是增强自身免疫力。化湿败毒颗粒是中医药对此次疫病理论和临床实践相结合而创新所得，也是中医药防治新冠肺炎临床、科研工作的重大进展。

研制该配方的团队由中国工程院院士、中国中医科学院院长黄璐琦担任领队。

若临床试验顺利成功，化湿败毒颗粒将可作为法定治疗新冠肺炎的有效药物。